The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible obstructive airways disease.-Reference-Cited by-同舟云学术

The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible obstructive airways disease.

Published:1987-10 Issue:4 Volume:24 Page:493-501
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:British Journal of Clinical Pharmacology

Author:

Neale MG,Brown K,Foulds RA,Lal S,Morris DA,Thomas D

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.1987.tb03203.x/fullpdf

Reference17 articles.

1. The clinical development of a new agent for the treatment of airway inflammation: nedocromil sodium (Tilade*);Auty;Eur. J. resp. Dis.,1986

2. Hepatic and renal clearance of sodium cromoglycate;Clark;J. Pharm. Pharmac.,1981

3. The effect of nedocromil sodium and sodium cromoglycate on antigen-induced bronchoconstriction in the Ascaris-sensitive monkey;Eady;Br. J. Pharmac.,1986

4. A double-blind group comparative trial comparing nedocromil sodium and placebo in the management of bronchial asthma;Fairfax;Eur. J. resp. Dis.,1986

5. Radioimmunoassay of nedocromil sodium;Gardner;J. Pharm. Biomed. Anal.,1987

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Pharmacokinetics of Inhaled Drugs;Journal of Aerosol Medicine and Pulmonary Drug Delivery;2023-10-01

2. Drivers of absolute systemic bioavailability after oral pulmonary inhalation in humans;European Journal of Pharmaceutics and Biopharmaceutics;2021-07

3. Model‐based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation;British Journal of Clinical Pharmacology;2016-06-23

4. Chromones: Cromoglycate and Nedocromil;Compendium of Inflammatory Diseases;2016

5. Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS;Journal of Pharmaceutical Sciences;2015-09